Literature DB >> 21722918

Association of Crohn's disease, thiopurines, and primary epstein-barr virus infection with hemophagocytic lymphohistiocytosis.

Vincent F Biank1, Mehul K Sheth, Julie Talano, David Margolis, Pippa Simpson, Subra Kugathasan, Michael Stephens.   

Abstract

OBJECTIVE: To assess the incidence of hemophagocytic lymphohistiocytosis (HLH) in a well-defined population of children with inflammatory bowel disease (IBD) and evaluate the common clinical and laboratory characteristics of individuals with IBD who developed HLH. STUDY
DESIGN: We conducted a retrospective study of all children who developed HLH over an 8-year period. The incidence of HLH in patients with IBD was calculated using US census data and a statewide project examining the epidemiology of pediatric IBD.
RESULTS: Among children in Wisconsin, 20 cases of HLH occurred during the study period; 5 cases occurred in children with IBD. Common characteristics include: Crohn's disease (CD), thiopurine administration, fever lasting more than 5 days, lymphadenopathy, splenomegaly, anemia, lymphopenia, and elevated serum triglycerides and ferritin. Of the patients, 4 had primary Epstein-Barr virus infections. The incidence of HLH among all children in Wisconsin was 1.5 per 100 000 per year. The risk was more than 100-fold greater for children with CD (P < .00001).
CONCLUSIONS: Pediatric patients with CD are at increased risk for developing HLH; primary Epstein-Barr virus infection and thiopurine administration may be risk factors.
Copyright © 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21722918      PMCID: PMC3191286          DOI: 10.1016/j.jpeds.2011.04.045

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  42 in total

Review 1.  The biology of Epstein-Barr virus: lessons learned from the virus and the host.

Authors:  J I Cohen
Journal:  Curr Opin Immunol       Date:  1999-08       Impact factor: 7.486

2.  [Macrophage activation syndrome after treatment with infliximab for fistulated Crohn's disease].

Authors:  Eric Chauveau; François Terrier; Didier Casassus-Buihle; Xavier Moncoucy; Bernard Oddes
Journal:  Presse Med       Date:  2005-04-23       Impact factor: 1.228

3.  Fever and progressive pancytopenia in a 20-year-old woman with Crohn's disease.

Authors:  Y W Sijpkens; C F Allaart; J Thompson; J van't Wout; P M Kluin; G J den Ottolander; R Bieger
Journal:  Ann Hematol       Date:  1996-04       Impact factor: 3.673

4.  HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society.

Authors:  J I Henter; M Aricò; R M Egeler; G Elinder; B E Favara; A H Filipovich; H Gadner; S Imashuku; G Janka-Schaub; D Komp; S Ladisch; D Webb
Journal:  Med Pediatr Oncol       Date:  1997-05

Review 5.  Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis.

Authors:  G Janka; S Imashuku; G Elinder; M Schneider; J I Henter
Journal:  Hematol Oncol Clin North Am       Date:  1998-04       Impact factor: 3.722

Review 6.  Familial hemophagocytic lymphohistiocytosis. Primary hemophagocytic lymphohistiocytosis.

Authors:  J I Henter; M Aricò; G Elinder; S Imashuku; G Janka
Journal:  Hematol Oncol Clin North Am       Date:  1998-04       Impact factor: 3.722

7.  Hemophagocytic lymphohistiocytosis in infancy and childhood.

Authors:  S Imashuku; S Hlbi; S Todo
Journal:  J Pediatr       Date:  1997-03       Impact factor: 4.406

Review 8.  X-linked lymphoproliferative disease: pathology and diagnosis.

Authors:  D M Maia; C P Garwacki
Journal:  Pediatr Dev Pathol       Date:  1999 Jan-Feb

9.  Hemophagocytic syndrome associated with fulminant ulcerative colitis and presumed acute pancreatitis.

Authors:  S Kanaji; K Okuma; Y Tokumitsu; S Yoshizawa; M Nakamura; Y Niho
Journal:  Am J Gastroenterol       Date:  1998-10       Impact factor: 10.864

Review 10.  Epstein-Barr virus and lymphoproliferative disease.

Authors:  D E Mosier
Journal:  Curr Opin Hematol       Date:  1999-01       Impact factor: 3.284

View more
  21 in total

1.  Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines.

Authors:  Andrew Wisniewski; Julien Kirchgesner; Philippe Seksik; Cécilia Landman; Anne Bourrier; Isabelle Nion-Larmurier; Philippe Marteau; Jacques Cosnes; Harry Sokol; Laurent Beaugerie
Journal:  United European Gastroenterol J       Date:  2019-11-14       Impact factor: 4.623

2.  Raising the Barr: An Unexpected Lesion at Ileal-Cecal Resection.

Authors:  V Mitsialis; Y Wu; B Gewurz; R Bleday; L A Doyle; R W Winter; M J Hamilton
Journal:  Dig Dis Sci       Date:  2019-02       Impact factor: 3.199

Review 3.  Update on the Use of Thiopurines and Methotrexate in Inflammatory Bowel Disease.

Authors:  Christopher M Johnson; Themistocles Dassopoulos
Journal:  Curr Gastroenterol Rep       Date:  2018-09-28

4.  Clinical and endoscopic complications of Epstein-Barr virus in inflammatory bowel disease: an illustrative case series.

Authors:  R L Goetgebuer; C J van der Woude; L de Ridder; M Doukas; A C de Vries
Journal:  Int J Colorectal Dis       Date:  2019-02-09       Impact factor: 2.571

Review 5.  Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease.

Authors:  H Matthew Cohn; Maneesh Dave; Edward V Loftus
Journal:  Inflamm Bowel Dis       Date:  2017-08       Impact factor: 5.325

6.  Crohn's disease complicated by Epstein-Barr virus-driven haemophagocytic lymphohistiocytosis successfully treated with rituximab.

Authors:  Grace Thompson; Dominic Pepperell; Ian Lawrence; Benjamin David McGettigan
Journal:  BMJ Case Rep       Date:  2017-02-22

7.  Seroprevalence of Epstein-Barr Virus, Cytomegalovirus, and Polyomaviruses in Children with Inflammatory Bowel Disease.

Authors:  Ondrej Hradsky; Ivana Copova; Kristyna Zarubova; Marianna Durilova; Jiri Nevoral; Miroslav Maminak; Petr Hubacek; Jiri Bronsky
Journal:  Dig Dis Sci       Date:  2015-06-20       Impact factor: 3.199

8.  Hemophagocytic lymphohistiocytosis caused by primary Epstein-Barr virus in patient with Crohn's disease.

Authors:  Francesco Virdis; Sara Tacci; Federico Messina; Massimo Varcada
Journal:  World J Gastrointest Surg       Date:  2013-11-27

9.  Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients.

Authors:  Ruben J Colman; Andrea Portocarrero-Castillo; Deepika Chona; Jennifer Hellmann; Phillip Minar; Michael J Rosen
Journal:  Inflamm Bowel Dis       Date:  2021-03-15       Impact factor: 5.325

Review 10.  Hemophagocytic Lymphohistiocytosis and Inflammatory Bowel Disease: Case Report and Systematic Review.

Authors:  Bárbara Brambilla; Amanda Machado Barbosa; Cassiano da Silva Scholze; Floriano Riva; Lislene Freitas; Raul Angelo Balbinot; Silvana Balbinot; Jonathan Soldera
Journal:  Inflamm Intest Dis       Date:  2020-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.